LCAT Enzyme Replacement Therapy Reduces LpX and Improves Kidney Function in a Mouse Model of Familial LCAT Deficiency
- 1 March 2019
- journal article
- research article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 368 (3) , 423-434
Abstract
Familial LCAT deficiency (FLD) is due to mutations in lecithin:cholesterol acyltransferase (LCAT), a plasma enzyme that esterifies cholesterol on lipoproteins. FLD is associated with markedly reduced levels of plasma high-density lipoprotein and cholesteryl ester and the formation of a nephrotoxic lipoprotein called LpX. We used a mouse model in which the LCAT gene is deleted and a truncated version of the SREBP1a gene is expressed in the liver under the control of a protein-rich/carbohydrate-low (PRCL) diet-regulated PEPCK promoter. This mouse was found to form abundant amounts of LpX in the plasma and was used to determine whether treatment with recombinant human LCAT (rhLCAT) could prevent LpX formation and renal injury. After 9 days on the PRCL diet, plasma total and free cholesterol, as well as phospholipids, increased 6.1 ± 0.6-, 9.6 ± 0.9-, and 6.7 ± 0.7-fold, respectively, and liver cholesterol and triglyceride concentrations increased 1.7 ± 0.4- and 2.8 ±0.9-fold, respectively, compared with chow-fed animals. Transmission electron microscopy revealed robust accumulation of lipid droplets in hepatocytes and the appearance of multilamellar LpX particles in liver sinusoids and bile canaliculi. In the kidney, LpX was found in glomerular endothelial cells, podocytes, the glomerular basement membrane, and the mesangium. The urine albumin/creatinine ratio increased 30-fold on the PRCL diet compared with chow-fed controls. Treatment of these mice with intravenous rhLCAT restored the normal lipoprotein profile, eliminated LpX in plasma and kidneys, and markedly decreased proteinuria. The combined results suggest that rhLCAT infusion could be an effective therapy for the prevention of renal disease in patients with FLD.Keywords
This publication has 45 references indexed in Scilit:
- Endothelial expression of human ABCA1 in mice increases plasma HDL cholesterol and reduces diet-induced atherosclerosisJournal of Lipid Research, 2012
- Effect of Recombinant Human Lecithin Cholesterol Acyltransferase Infusion on Lipoprotein Metabolism in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Apolipoprotein E Is the Major Physiological Activator of Lecithin−Cholesterol Acyltransferase (LCAT) on Apolipoprotein B LipoproteinsBiochemistry, 2004
- ACAT2 deficiency limits cholesterol absorption in the cholesterol-fed mouse: Impact on hepatic cholesterol homeostasisHepatology, 2004
- Lipoprotein–X in Patients With Cirrhosis: Its Relationship to Cholestasis and HypercholesterolemiaHepatology, 1998
- Cell-derived unesterified cholesterol cycles between different HDLs and LDL for its effective esterification in plasma.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1993
- Lipoprotein-XCRC Critical Reviews in Clinical Laboratory Sciences, 1979
- Lipoprotein‐X: a substrate for lecithin: cholesterol acyltransferaseEuropean Journal of Clinical Investigation, 1977
- Identification of the abnormal cholestatic lipoprotein (LP‐X) in familial lecithin:Cholesterol acyltransferase deficiencyFEBS Letters, 1972
- A lipoprotein characterizing obstructive jaundice. II. Isolation and partial characterization of the protein moieties of low density lipoproteinsJournal of Clinical Investigation, 1970